Skip to main
GMED
GMED logo

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. is poised for a favorable outlook due to the potential for accelerated growth in the spine market and increased sales from its Enabling Technologies segment, which could lead to enhanced profit margins. The company demonstrates robust financial health, highlighted by strong free cash flow (FCF) growth and an FCF yield of 8%, while trading below historical valuation levels. Despite recent earnings results slightly missing consensus expectations, the overall trajectory suggests continued profit upside, indicating an optimistic long-term perspective for the company's financial performance.

Bears say

The financial analysis indicates a negative outlook for Globus Medical Inc, primarily driven by several key risks, including slower than anticipated growth in the spine market and revenue dis-synergies linked to the NuVasive merger. Furthermore, the company's sales in its Enabling Technologies segment have not met expectations, leading to concerns about continued growth and overall margin expansion. The potential for competitive pressures to escalate, along with underwhelming product launches and delays in market penetration for new musculoskeletal offerings, further exacerbates the negative financial landscape for the company.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.